CardioNet Appoints Two Directors to Board
August 21 2008 - 5:08PM
PR Newswire (US)
Industry veterans bring product marketing and financial expertise
to Board CONSHOHOCKEN, Pa., Aug. 21 /PRNewswire-FirstCall/ --
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical
technology company with an initial focus on the diagnosis and
monitoring of cardiac arrhythmias, announced today that it has
named Ronald Ahrens and Kirk Gorman to its Board of Directors. The
appointments of Mr. Ahrens and Mr. Gorman increase CardioNet's
Board to a total of nine members. Arie Cohen, CardioNet President
and CEO, commented, "Ron and Kirk are tremendous additions to our
Board, and we are very pleased and fortunate to have the
opportunity to gain from their years of experience across a broad
spectrum of healthcare and business disciplines. Their
appointments, along with the recent naming of Randy Thurman as
Executive Chairman, serve to further strengthen and diversify our
Board as we continue to execute our growth strategy and establish
CardioNet's mobile cardiac outpatient telemetry system as the
best-in-class in the arrhythmia monitoring market." A healthcare
industry veteran with over forty years of senior executive and
management experience, Mr. Ahrens most recently served as President
of Merck Consumer Healthcare Group Worldwide. Prior to his tenure
at Merck, Mr. Ahrens held several positions within Bristol Myers
Squibb, including Consumer Group President North America and
President, Bristol Myers Products Division. In addition, Mr. Ahrens
has held executive and management positions at Richardson Vicks and
Procter & Gamble. Mr. Ahrens has also established a strong
track record on several Boards of Directors. Currently, he serves
as a Non-Executive Advisor to the Board of Johnson & Johnson
Merck, and is a Board member of Temptime Corporation, a privately
held company that supplies vaccine vial monitors, and ULURU, Inc.,
an AMEX-listed specialty pharmaceutical company specializing in
wound care. Previously, Mr. Ahrens was on the Boards of VIASYS
Healthcare, Closure Medical Corporation, St. Ives and Alcide. Mr.
Gorman is currently Senior Vice President and Chief Financial
Officer of Jefferson Health Systems, the largest hospital system in
Philadelphia. Prior to Jefferson Health Systems, he was Senior Vice
President and Chief Financial Officer of Universal Health Services,
the country's fifth largest investor owned hospital chain, and
President, Chief Financial Officer and member of the Board of
Trustees of Universal Health Realty Income Trust, a NYSE-listed
healthcare REIT. Mr. Gorman began his career with Mellon Bank,
where he served in numerous credit, cash management, and corporate
banking functions. Mr. Gorman also brings extensive Board
experience to CardioNet. Currently, he serves as Chairman of the
Board of Care Investment Trust, a NYSE-listed healthcare REIT, and
is a member of the board of IASIS Healthcare LLC, an owner and
operator of community-focused hospitals. Mr. Gorman also served on
the Boards of VIASYS Healthcare, Physician Dialysis, Inc. and HCF
Guernsey, Ltd. About CardioNet CardioNet, Inc. is a leading
provider of ambulatory, continuous, real-time outpatient management
solutions for monitoring relevant and timely clinical information
regarding an individual's health. CardioNet's initial efforts are
focused on the diagnosis and monitoring of cardiac arrhythmias, or
heart rhythm disorders, with a solution that it markets as the
CardioNet System. More information can be found at
http://www.cardionet.com/ . Forward Looking Statements This press
release includes certain forward-looking statements within the
meaning of the "Safe Harbor" provisions of the Private Securities
Litigation Reform Act of 1995 regarding, among other things, our
growth prospects and the prospects for our products. Such
forward-looking statements are based on current expectations and
involve inherent risks and uncertainties, including important
factors that could delay, divert, or change any of them, and could
cause actual outcomes and results to differ materially from current
expectations. These factors include, among other things, the
success of our sales and marketing initiatives, our ability to
attract and retain talented sales personnel, market factors,
internal research and development initiatives, partnered research
and development initiatives, competitive product development,
changes in governmental regulations and legislation, the continued
consolidation of payors, acceptance of our new products and
services, patent protection and litigation. For further details and
a discussion of these and other risks and uncertainties, please see
our public filings with the Securities and Exchange Commission,
including our Annual Reports on Form 10-K and Quarterly Reports on
Form 10-Q. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise. Contact: CardioNet, Inc. Marty Galvan
Investor Relations 800-908-7103 DATASOURCE: CardioNet, Inc.
CONTACT: Marty Galvan, Investor Relation, of CardioNet, Inc.,
+1-800-908-7103, Web site: http://www.cardionet.com/
Copyright
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024